Bayer reported a net profit of 219 million euros ($252.1 million) in the second quarter, a turnaround from the 199 million euros loss opposited a year earlier. The shift was largely due to a reduction in special charges—mainly litigation‑related expenses—down to 172 million euros from 981 million euros a year before. The German conglomerate noted that its 2026 sales and earnings forecasts remain unchanged once currency effects are adjusted, and that year‑end net debt is expected to be lower than initially projected.

Weeks after the U.S. Supreme Court ruled in Bayer’s favor in a long‑standing case over its Roundup weedkiller, the company emphasized progress toward resolving its legal challenges. The ruling removed a significant liability component, contributing to the sharper financial performance. Bayer also highlighted that the lower litigation burden is part of a broader strategy to stabilize earnings as it navigates regulatory and market pressures.

The company’s updated outlook signals confidence in maintaining its fiscal trajectory while managing ongoing legal exposure. Investors and analysts will watch how the reduced litigation costs continue to influence future quarterly results.